JP2017195888A5 - - Google Patents

Download PDF

Info

Publication number
JP2017195888A5
JP2017195888A5 JP2017106384A JP2017106384A JP2017195888A5 JP 2017195888 A5 JP2017195888 A5 JP 2017195888A5 JP 2017106384 A JP2017106384 A JP 2017106384A JP 2017106384 A JP2017106384 A JP 2017106384A JP 2017195888 A5 JP2017195888 A5 JP 2017195888A5
Authority
JP
Japan
Prior art keywords
nucleic acid
tumor
recombinant listeria
listeria strain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017106384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017195888A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017195888A publication Critical patent/JP2017195888A/ja
Publication of JP2017195888A5 publication Critical patent/JP2017195888A5/ja
Pending legal-status Critical Current

Links

JP2017106384A 2008-05-19 2017-05-30 異種抗原のための二重送達システム Pending JP2017195888A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7179208P 2008-05-19 2008-05-19
US61/071,792 2008-05-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015067888A Division JP6182172B2 (ja) 2008-05-19 2015-03-30 異種抗原のための二重送達システム

Publications (2)

Publication Number Publication Date
JP2017195888A JP2017195888A (ja) 2017-11-02
JP2017195888A5 true JP2017195888A5 (enExample) 2017-12-14

Family

ID=41340826

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011510653A Active JP5757863B2 (ja) 2008-05-19 2009-05-19 異種抗原のための二重送達システム
JP2015067888A Active JP6182172B2 (ja) 2008-05-19 2015-03-30 異種抗原のための二重送達システム
JP2017106384A Pending JP2017195888A (ja) 2008-05-19 2017-05-30 異種抗原のための二重送達システム

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011510653A Active JP5757863B2 (ja) 2008-05-19 2009-05-19 異種抗原のための二重送達システム
JP2015067888A Active JP6182172B2 (ja) 2008-05-19 2015-03-30 異種抗原のための二重送達システム

Country Status (6)

Country Link
US (2) US20110129499A1 (enExample)
EP (2) EP2288379A4 (enExample)
JP (3) JP5757863B2 (enExample)
DK (1) DK2853269T3 (enExample)
ES (1) ES2741730T3 (enExample)
WO (1) WO2009143167A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US20120135033A1 (en) * 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9084747B2 (en) 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
EP2403935B1 (en) * 2009-03-04 2017-05-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011100754A1 (en) * 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
MX2014011061A (es) 2012-03-12 2016-09-29 Advaxis Inc Inhibicion de funcion de celula supresora despues de tratamiento con vacuna listeria.
KR20160130774A (ko) * 2014-02-18 2016-11-14 어드박시스, 인크. 바이오마커 지도된 다중-표적 면역치료
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
US9907849B2 (en) 2014-07-18 2018-03-06 Advaxis, Inc. Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
SG11201700092XA (en) * 2014-07-18 2017-02-27 Advaxis Inc Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US20180305702A1 (en) * 2015-09-15 2018-10-25 Advaxis, Inc. Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment
AU2016340148A1 (en) * 2015-10-14 2018-05-31 Advaxis, Inc. Recombinant Listeria strains and methods of using the same in cancer immunotherapy
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN111356760A (zh) 2017-09-19 2020-06-30 阿德瓦希斯公司 细菌或李斯特菌菌株的冻干组合物和方法
EP3694532B1 (en) 2017-10-10 2025-02-26 Gritstone bio, Inc. Neoantigen identification using hotspots
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing junction epitope presentation for neoantigens
CN111349645B (zh) * 2018-12-24 2022-05-17 上海若泰医药科技有限公司 一种提高非整合减毒李斯特菌疫苗安全性的方法

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1156952A (en) 1979-06-08 1983-11-15 Zacharia M. George Formation of coke from heavy crude oils in the presence of calcium carbonate
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5262177A (en) 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
FR2686896B1 (fr) 1992-01-31 1995-01-06 Pasteur Institut Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
WO1996039154A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
EP0832255B1 (en) 1995-06-07 2005-12-14 Washington University Recombinant bacterial system with environmentally limited viability
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
DE19541450C2 (de) 1995-11-07 1997-10-02 Gsf Forschungszentrum Umwelt Genkonstrukt und dessen Verwendung
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6740506B2 (en) * 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
EP1860192A1 (en) 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
WO1998046811A1 (fr) * 1997-04-17 1998-10-22 Sekisui Chemical Co., Ltd. Particules conductrices, procede et dispositif de fabrication, structure anisotrope a adhesif et raccordement conducteur, composants de circuit electronique et leur procede de fabrication
DE69734605T2 (de) 1997-04-18 2006-08-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
EP0934421A1 (en) 1997-08-06 1999-08-11 Laboratorio Medinfar-Produtos Farmaceuticos LDA. DNA INTEGRATION INTO "MYCOBACTERIUM spp." GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US20040013685A1 (en) 1997-11-10 2004-01-22 Peter Andersen Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
KR100483494B1 (ko) 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
WO2000049158A2 (en) 1999-02-18 2000-08-24 Compugen Ltd. Psa and klk-2 splicing variants
IL150109A0 (en) 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
EP1278769A2 (en) 2000-04-19 2003-01-29 Statens Serum Institut Tuberculosis antigens and methods of use thereof
US7199229B2 (en) 2000-08-11 2007-04-03 Mount Sinai Hospital Kallikrein gene
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
FR2825633B1 (fr) 2001-06-11 2005-12-16 Bio Veto Tests Bvt Complexe vaccinal therapeutique destine a la prevention et au traitement des leishmanioses et des infections a microorganismes pathogenes intracellulaires chez le mammifere
WO2003065787A2 (en) 2002-02-06 2003-08-14 Johns Hopkins University School Of Medicine Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
CA2486980A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
EP2243493A1 (en) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
EP1408048A1 (en) 2002-10-07 2004-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
CA2512812A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
DE10310261A1 (de) 2003-03-05 2004-09-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Identifizierung von Antigen-Epitopen
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
US7611712B2 (en) 2003-10-23 2009-11-03 Nelson M. Karp Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide
WO2005061534A2 (en) 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
MXPA06007144A (es) 2003-12-24 2007-01-31 Cerus Corp Moleculas de acido nucleico recombinante que codifican proteinas de fusion que comprenden polipeptidos de senal secretoria bacterial y de antigenos, casetes de expresion y bacterias, y metodos para usar las mismas.
US7855064B2 (en) * 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
EP2942391B1 (en) * 2004-08-13 2018-05-23 The Trustees Of The University Of Pennsylvania Methods for constructing antibiotic resistance free vaccines
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
EP1802338A4 (en) 2004-10-18 2010-01-27 Medimmune Inc CELL SEALING PROCESS FOR THE GROWTH OF LISTERIES
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN100424096C (zh) 2005-06-16 2008-10-08 华东理工大学 含有hiv转导结构域的生存素突变体及制备方法和应用
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2007061848A2 (en) 2005-11-17 2007-05-31 The Trustees Of The University Of Pennsylvania Methods for producing, growing, and preserving listeria vaccine vectors
RU2006112025A (ru) * 2005-12-16 2007-10-27 Хелт Рисерч Инк. (Us) Пептиды для стимуляции иммунного ответа против меланомы
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
ES2532942T3 (es) * 2006-03-01 2015-04-06 Aduro Biotech Listeria obtenida por ingeniería genética y métodos de uso de la misma
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
NZ574140A (en) 2006-07-05 2012-02-24 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
US20080124354A1 (en) 2006-07-10 2008-05-29 Yvonne Paterson Methods for administering tumor vaccines
WO2008094188A2 (en) 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Methods and compositions using listeria for enhancing immunogenicity by prime boost
JP2009545330A (ja) 2006-08-04 2009-12-24 ザ トラスティーズ オブ ザ ユニバーシティー オブ ぺンシルべニア Ｉｇｅ依存性疾患を治療するための方法および組成物
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
WO2008130551A2 (en) * 2007-04-16 2008-10-30 The Trustees Of The University Of Pennsylvania Antibiotic resistance free listeria strains and methods for constructing and using same
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
WO2009110950A1 (en) 2007-12-31 2009-09-11 The Trustees Of The University Of Pennsylvania Attenuated listeria strain and adenovirus strain vaccines and methods of use
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
US9084747B2 (en) 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
FI4209510T3 (fi) 2008-12-09 2024-03-22 Hoffmann La Roche Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
WO2011100754A1 (en) 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
TW202114735A (zh) 2011-08-01 2021-04-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CN104955835B (zh) 2012-12-27 2020-04-17 艾杜罗生物科技公司 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法

Similar Documents

Publication Publication Date Title
JP2017195888A5 (enExample)
JP2016156828A5 (enExample)
JP2017513502A5 (enExample)
JP2017507943A5 (enExample)
Tiptiri-Kourpeti et al. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy
JP2013526837A5 (enExample)
JP2018508212A5 (enExample)
RU2016145464A (ru) Рекомбинантные вакцинные штаммы listeria и способы их получения
RU2016137834A (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
JP2021502083A5 (enExample)
JP2017507918A (ja) Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン
PH12017500484A1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
JP2015096070A5 (enExample)
WO2007106476A2 (en) Compositions and methods for enhancing the immunogenicity of antigens
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
JP2008543314A5 (enExample)
WO2009002418A3 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
WO2019094607A3 (en) Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
JP2016146837A5 (enExample)
JP2020528911A5 (enExample)
MX2017000838A (es) Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas.
WO2005028505A3 (en) Multiepitope polypeptides for cancer immunotherapy
EP4599845A3 (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP2015506705A5 (enExample)
JP2018536002A5 (enExample)